Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.195 EUR | 0.00% | +2.58% | -27.79% |
09/05 | Ulisse Biomed, Sbaizero resigns as independent director | AN |
03/05 | Ulysses Biomed reduces loss in 2023; NFP is positive | AN |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 24.11 | 8.209 | 25.78 | 25.78 | - |
Enterprise Value (EV) 1 | 19.12 | 4.415 | 23.58 | 23.41 | 22.89 |
P/E ratio | - | - | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | 58.1 x | 15.7 x | 75.6 x | 18.1 x | 15.1 x |
EV / Revenue | 46.1 x | 8.43 x | 69.2 x | 16.5 x | 13.4 x |
EV / EBITDA | -53.7 x | -4.47 x | -15.9 x | 37.5 x | 25.2 x |
EV / FCF | -13.5 x | -4.21 x | -14.7 x | 139 x | 44 x |
FCF Yield | -7.38% | -23.8% | -6.79% | 0.72% | 2.27% |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 7,250 | 8,064 | 21,570 | 21,570 | - |
Reference price 2 | 3.325 | 1.018 | 1.195 | 1.195 | 1.195 |
Announcement Date | 28/03/22 | 28/03/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales 1 | 0.7627 | 0.4148 | 0.5238 | 0.341 | 1.421 | 1.706 |
EBITDA 1 | - | -0.3557 | -0.9868 | -1.483 | 0.625 | 0.909 |
EBIT 1 | - | -0.6034 | -1.306 | -1.821 | 0.264 | 0.524 |
Operating Margin | - | -145.47% | -249.42% | -534.02% | 18.58% | 30.72% |
Earnings before Tax (EBT) | - | -0.6036 | -1.308 | - | - | - |
Net income 1 | 0.2218 | -0.6036 | -1.308 | -1.814 | 0.269 | 0.53 |
Net margin | 29.09% | -145.51% | -249.68% | -531.96% | 18.93% | 31.07% |
EPS | - | - | - | - | - | - |
Free Cash Flow 1 | - | -1.411 | -1.049 | -1.602 | 0.168 | 0.52 |
FCF margin | - | -340.22% | -200.23% | -469.79% | 11.82% | 30.48% |
FCF Conversion (EBITDA) | - | - | - | - | 26.88% | 57.21% |
FCF Conversion (Net income) | - | - | - | - | 62.45% | 98.11% |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 08/08/21 | 28/03/22 | 28/03/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 S1 |
---|---|
Net sales | - |
EBITDA | - |
EBIT | - |
Operating Margin | - |
Earnings before Tax (EBT) 1 | -0.8996 |
Net income 1 | -0.8996 |
Net margin | - |
EPS | - |
Dividend per Share | - |
Announcement Date | 29/09/23 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | 4.99 | 3.79 | 2.19 | 2.37 | 2.89 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | - | -1.41 | -1.05 | -1.6 | 0.17 | 0.52 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | 1.04 | 0.08 | 0.15 | 0.1 | 0.1 |
Capex / Sales | - | 251.26% | 14.95% | 44.28% | 7.04% | 5.86% |
Announcement Date | 08/08/21 | 28/03/22 | 28/03/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.79% | 28M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- UBM Stock
- Financials Ulisse Biomed S.p.A.